# A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

> clinical trial · VERIFIED · 2026-06-25

Status: NOT_YET_RECRUITING · Sponsor: Moonlight Bio, Inc · Condition: Small Cell Lung Cancer (SCLC )

- Company: Moonlight Bio, Inc
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07488923

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.